AU2001253127A1 - Soluble zalpha11 cytokine receptors - Google Patents

Soluble zalpha11 cytokine receptors

Info

Publication number
AU2001253127A1
AU2001253127A1 AU2001253127A AU5312701A AU2001253127A1 AU 2001253127 A1 AU2001253127 A1 AU 2001253127A1 AU 2001253127 A AU2001253127 A AU 2001253127A AU 5312701 A AU5312701 A AU 5312701A AU 2001253127 A1 AU2001253127 A1 AU 2001253127A1
Authority
AU
Australia
Prior art keywords
methods
vitro
vivo
soluble zalpha11
cytokine receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253127A
Inventor
Richard D Holly
Andrew J. Nelson
Julia E. Novak
Scott R. Presnell
Cindy A Sprecher
James W. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of AU2001253127A1 publication Critical patent/AU2001253127A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zalpha11 receptors that may be used as novel cytokine antagonist, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block zalpha11 Ligand activity in vitro and in vivo, and may be used in conjunction with zalpha11 Ligand and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
AU2001253127A 2000-04-05 2001-04-03 Soluble zalpha11 cytokine receptors Abandoned AU2001253127A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19473100P 2000-04-05 2000-04-05
US60194731 2000-04-05
US22212100P 2000-07-28 2000-07-28
US60222121 2000-07-28
PCT/US2001/010872 WO2001077171A2 (en) 2000-04-05 2001-04-03 Soluble zalpha11 cytokine receptors

Publications (1)

Publication Number Publication Date
AU2001253127A1 true AU2001253127A1 (en) 2001-10-23

Family

ID=26890341

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253127A Abandoned AU2001253127A1 (en) 2000-04-05 2001-04-03 Soluble zalpha11 cytokine receptors

Country Status (9)

Country Link
US (9) US6777539B2 (en)
EP (2) EP1303602B1 (en)
AT (2) ATE456654T1 (en)
AU (1) AU2001253127A1 (en)
CA (1) CA2420992C (en)
DE (2) DE60141234D1 (en)
DK (2) DK1749888T3 (en)
ES (2) ES2279809T3 (en)
WO (1) WO2001077171A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
CA2237915A1 (en) * 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
DK1749888T3 (en) * 2000-04-05 2010-05-10 Zymogenetics Inc Soluble Zalph11a cytokine receptors
EP1787997A1 (en) * 2000-05-11 2007-05-23 Genetics Institute, LLC MU-1, member of the cytokine receptor family
CA2441265A1 (en) * 2001-03-16 2002-09-26 Basf Plant Science Gmbh Sugar and lipid metabolism regulators in plants
NZ532021A (en) * 2001-10-04 2008-05-30 Genetics Inst Llc Methods and compositions for modulating interleukin-21 receptor activity
JP2005530716A (en) * 2002-03-27 2005-10-13 アメリカ合衆国 Methods for treating cancer in humans
AU2003243415A1 (en) 2002-06-07 2003-12-22 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
WO2004003156A2 (en) 2002-07-01 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Il-21 as a regulator of immunoglobin production
CN1688340A (en) 2002-07-15 2005-10-26 韦思公司 Methods and compositions for modulating T helper (TH) cell development and function
ES2340280T3 (en) * 2003-03-14 2010-06-01 Wyeth Llc DIRECTED ANTIBODIES AGAINST THE RECEIVER OF HUMAN IL-21 AND USE OF THE SAME.
US20060159655A1 (en) * 2003-03-21 2006-07-20 Wyeth Treating immunological disorders using agonists of interleukin-21 / interleukin-21 receptor
US7993919B2 (en) * 2003-11-19 2011-08-09 The United States Of America As Represented By The Department Of Health And Human Services Method of inducing memory B cell development and terminal differentiation
JP2008501042A (en) * 2004-05-19 2008-01-17 ワイス Regulation of immunoglobulin production and atopic diseases
JP4982373B2 (en) 2004-05-20 2012-07-25 ザイモジェネティクス， インコーポレイテッド Methods of treating cancer using IL-21 and monoclonal antibody therapy
KR20070057789A (en) * 2004-08-05 2007-06-07 와이어쓰 Antagonizing interleukin-21 receptor activity
CA3066594A1 (en) * 2004-10-08 2006-04-20 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
GT200600148A (en) * 2005-04-14 2006-11-22 METHODS FOR THE TREATMENT AND PREVENTION OF FIBROSIS
EP1960433A2 (en) * 2005-11-28 2008-08-27 Zymogenetics, Inc. Il-21 receptor antagonists
ES2409835T3 (en) 2005-11-28 2013-06-28 Zymogenetics, Inc. IL-21 antagonists
JP2009532680A (en) * 2006-03-31 2009-09-10 フェラーニ−カイル，カリマ Methods and compositions for obtaining and using bioactive multiprotein complexes
CA2910933C (en) * 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
AR071885A1 (en) * 2008-05-23 2010-07-21 Wyeth Corp PROTEINS OF UNION TO THE INTERLEUQUINE RECEIVER 21
EP2296689A1 (en) * 2008-05-23 2011-03-23 Wyeth LLC Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2010044472A1 (en) 2008-10-16 2010-04-22 Ｈｏｙａ Ｃａｎｄｅｏ Ｏｐｔｒｏｎｉｃｓ株式会社 Polarizing glass and optical isolator
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2611934A1 (en) * 2010-09-03 2013-07-10 Confarma France Quantification of residual host cell dna by real-time quantitative pcr
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
US11208632B2 (en) 2016-04-26 2021-12-28 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5783672A (en) * 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
WO1998031811A1 (en) 1997-01-16 1998-07-23 Genetics Institute, Inc. Member of the hematopoietin receptor superfamily
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
EP1088831A4 (en) 1998-06-24 2003-01-02 Chugai Pharmaceutical Co Ltd Novel hemopoietin receptor proteins
AU5104799A (en) 1998-08-04 2000-02-28 Regeneron Pharmaceuticals, Inc. Novel orphan cytokine receptors
EA201001190A1 (en) 1998-09-23 2011-04-29 Займодженетикс, Инк. ISOLATED ANTIBODY, SPECIFICALLY ASSOCIATED WITH POLYPEPTIDE, CONTAINING FROM THE SEQUENCE OF AMINO ACID RESIDUES
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
IL142584A0 (en) 1998-11-06 2002-03-10 Basf Ag Tricyclic pyrazole derivatives
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2000069880A1 (en) * 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
DK1749888T3 (en) * 2000-04-05 2010-05-10 Zymogenetics Inc Soluble Zalph11a cytokine receptors

Also Published As

Publication number Publication date
ES2279809T3 (en) 2007-09-01
ATE349522T1 (en) 2007-01-15
CA2420992A1 (en) 2001-10-18
ATE456654T1 (en) 2010-02-15
WO2001077171A2 (en) 2001-10-18
US20020137677A1 (en) 2002-09-26
US7629452B2 (en) 2009-12-08
US20070224118A1 (en) 2007-09-27
US20110003973A1 (en) 2011-01-06
US20110189207A1 (en) 2011-08-04
US20090196882A1 (en) 2009-08-06
US20090221802A1 (en) 2009-09-03
US20080032333A1 (en) 2008-02-07
EP1749888A3 (en) 2007-03-14
ES2339959T3 (en) 2010-05-27
US20040235743A1 (en) 2004-11-25
WO2001077171A3 (en) 2002-05-16
US7189695B2 (en) 2007-03-13
DK1303602T3 (en) 2007-05-07
EP1303602A2 (en) 2003-04-23
US20100074905A1 (en) 2010-03-25
DK1749888T3 (en) 2010-05-10
DE60125543D1 (en) 2007-02-08
CA2420992C (en) 2010-07-13
US6777539B2 (en) 2004-08-17
US7763713B2 (en) 2010-07-27
EP1303602B1 (en) 2006-12-27
EP1749888A2 (en) 2007-02-07
EP1749888B1 (en) 2010-01-27
DE60141234D1 (en) 2010-03-18
DE60125543T2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
EP1749888A3 (en) Soluble zalpha11 cytokine receptors
WO2002012345A3 (en) Soluble zcytor 11 cytokine receptors
IL163067A (en) Isolated heterodimeric cytokine receptor
UA84387C2 (en) Human cytokine as a ligand of zalpha receptor and use thereof
WO2002000721A3 (en) Cytokine receptor zcytor17
AU2002241533A1 (en) Cytonkine receptor zcytor19
AU3009397A (en) Hematopoietic cytokine receptor
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
WO2000017235A3 (en) Cytokine receptor zalpha11
EP1746160A3 (en) Hepatocyte growth factor receptor antagonists and uses thereof
HK1014984A1 (en) Receptor ligand vegf-c
OA09704A (en) Antibody antagonist of human interleukin-4.
EP0759942A4 (en) Interleukin-15 receptors
WO2003089603A3 (en) Cytokine receptor
TR199901636T2 (en) Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin bound antibodies as therapeutic agents for the treatment of immunological diseases .
IL113252A0 (en) Eph receptors binding ligands
JPS6463395A (en) Oncostatin m and novel composition having antitumor activity
EP1736545A3 (en) Soluble zcytor 11 cytokine receptors
UA84540C2 (en) Novel cytokine zcytor17 ligand
WO2005051994A3 (en) Ztnf11, a tumor necrosis factor
WO2001040278A3 (en) Human semaphorin zsmf-16